Global RDH12 Alliance Deal History & Licensing Activity
Global RDH12 Alliance is a life sciences. Over the past three years, Global RDH12 Alliance has been involved in 2 licensing and acquisition transactions, with a primary focus on Gene Therapy (4 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Gene Therapy
Focus Area
Ophthalmology
Global RDH12 Alliance Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Global RDH12 Alliance in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| OPGx-RDH12 | Opus Genetics | Gene Therapy | Preclinical | collaboration | Jul 2025 |
| OPGx-RDH12 | Opus Genetics | Gene Therapy | Preclinical | collaboration | Jun 2025 |
Global RDH12 Alliance Pipeline Focus
Therapeutic areas and modalities where Global RDH12 Alliance is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Global RDH12 Alliance Strategic Signals
Key indicators of Global RDH12 Alliance's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Global RDH12 Alliance's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Ophthalmology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Global RDH12 Alliance Licensing & Deal Activity
Global RDH12 Alliance is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Global RDH12 Alliance ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Global RDH12 Alliance include Ophthalmology (4 deals and trials). In terms of modality, Global RDH12 Alliance has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Global RDH12 Alliance and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Global RDH12 Alliance's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.